nabu.science
MethodologyAboutContact

 

  • Snapshot
  • Key Claims
  • Strengths & Limitations
  • Commentary
  • From the Authors
  • Author Note / Field Feedback
  • Dimension breakdown
  • Impact Profile
Free · About 5 minutes
Report #NBU-EDAAA5C2·Framework v5.9·Pipeline v0.4·Evaluated 08 Oct 2026·OECD: 3.2 Clinical medicine·Subfield: Aging·Basis: Full text·Type: Observational cohort study

Associations of proteomic age clocks with lifestyle risk factors, incident chronic diseases and mortality in two European cohorts.

Robinson et al.Robinson, Xiao, Homann et al.·2026·Nature aging·10.1038/s43587-026-01163-6 ↗

Primary claim

the global age gap, an age acceleration score combining proteomic clocks, was associated with smoking, alcohol consumption, physical inactivity and higher risk of mortality, cardiovascular diseases, dementia and cancers of the liver, upper aero-digestive tract, lung and kidney.

Supported · prospective disease associations are consistent, while lifestyle associations are cross-sectional and residual confounding remains
In brief

A rigorous cross-disease validation of proteomic age clocks that strengthens their biomarker case, while modest incremental prediction limits near-term clinical value.

ReliabilityCaveats4 of 4 checks completeRead the 2 entries ↓
Likely to hold — the claim's weakest requirement is that the effect exists at all. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.
Abstract

Assessment of biological aging using proteomic clocks may enhance risk prediction and elucidate the molecular links between aging and chronic diseases. Here, among 17,473 participants of the European Prospective Investigation into Cancer and Nutrition, we examined associations of plasma SomaScan-based proteomic clocks, including organ-specific clocks, with risk factors, 24 incident chronic diseases and all-cause mortality, over up to 28 years of follow-up. Replication was conducted in the Whitehall II study. We show that the global age gap, an age acceleration score combining proteomic clocks, was associated with smoking, alcohol consumption, physical inactivity and higher risk of mortality, cardiovascular diseases, dementia and cancers of the liver, upper aero-digestive tract, lung and kidney. Lung, kidney and stomach cancers were more strongly associated with related organ-specific age gaps. Predictive performance of proteomic clocks for mortality was comparable to that of classical lifestyle risk factors. In summary, proteomic clocks appear promising biomarkers of generalized age-related disease risk.

Key Claims

Primary finding · Supported

the global age gap, an age acceleration score combining proteomic clocks, was associated with smoking, alcohol consumption, physical inactivity and higher risk of mortality, cardiovascular diseases, dementia and cancers of the liver, upper aero-digestive tract, lung and kidney.

Likely to hold — the claim's weakest requirement is that the effect exists at all. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.

prospective disease associations are consistent, while lifestyle associations are cross-sectional and residual confounding remains

Abstract
Quote verified
Secondary · Supported

Lung, kidney and stomach cancers were more strongly associated with related organ-specific age gaps.

organ-specific hazard ratios support the pattern, but formal between-clock comparisons are limited

Abstract; Results, Associations of organ-specific proteomic age gaps; Figure 6c–e
Quote verified
Secondary · Supported

Predictive performance of proteomic clocks for mortality was comparable to that of classical lifestyle risk factors.

both models achieved a 0.73 C-index, though evaluation appears in-sample and case–cohort weighting is unclear

Abstract; Results, Comparison of mortality prediction models; Figure 6j
Quote verified
Secondary · Tentative

This adds further support for both the use of proteomic clocks to assess biological age and to the Geroscience hypothesis that biological aging itself is a root cause of many age-related diseases.

a correlation across disease estimates cannot establish biological aging as a root cause

Discussion, paragraph beginning “We observed a significant correlation”
Quote verified

Derived from the full evaluation — not a separate score.

Strengths · Limitations

Strengths

#contribution

Broad prospective cross-disease evaluation

Five conventional clocks, a Global ensemble, and organ-specific clocks are evaluated against mortality and 24 incident diseases over as much as 28 years of follow-up.

↳ Abstract; Results, Study population; Figures 3–6

#methodological rigour

Appropriate case–cohort analytical framework

The analysis uses a random subcohort, Prentice weighting, age as the time scale, prespecified risk-factor adjustment, and FDR correction across endpoints.

↳ Methods, Study population; Methods, Statistics and reproducibility

#methodological rigour

Replication and sensitivity analyses

Mortality associations replicate in Whitehall II, while two- and five-year lag analyses and restriction to never-smokers test reverse causation and smoking-related confounding.

↳ Results, Whitehall II mortality analysis; Extended Data Figures 6–8

Limitations

#application pathway

Prediction gain remains clinically modest

Adding the Global age gap to classical risk factors increases the mortality C-index only from 0.73 to 0.74, without evidence that this changes clinical decisions or outcomes.

↳ Results, Comparison of mortality prediction models; Figure 6j

#positioning

Lifestyle inference exceeds cross-sectional evidence

Lifestyle factors and proteomic age were measured at baseline, so statements that healthier behavior may slow biological aging remain hypotheses despite explicit causal caveats.

↳ Results, Associations of risk factors; Discussion, lifestyle and limitations paragraphs

#reporting

Localized reporting inconsistencies reduce precision

The concluding organ-cancer list substitutes liver for stomach, the mortality discussion overlooks the intestine-clock exception, and captions blur 24 diseases with 25 total endpoints.

↳ Abstract; Figure 6; Discussion, organ-specific paragraph and final paragraph

Does this match your read? Add your assessment ↓

Nabu Commentary

The strongest evidence comes from the large prospective case–cohort analysis, appropriate weighting and adjustment, lag analyses, and independent replication of mortality associations. The broad cross-clock and cross-disease comparison is a meaningful extension, although the Global ensemble offers only marginally stronger associations than existing clocks. Reporting and contextualization are reduced by localized endpoint inconsistencies and by lifestyle and geroscience interpretations that go beyond what cross-sectional or correlational analyses can establish. Clinical impact remains early because the Global age gap improves mortality discrimination only from 0.73 to 0.74 when added to standard risk factors.

Evaluate another paper

Free · About 5 minutes · Research preview

Author Note / Field Feedback

Nabu’s assessment, alongside the field’s view.

Are you an author of this paper?

Dimension breakdown

Evidence Score

Out of 5
012345
3.8±0.2

Contribution
3.8

The study meaningfully extends the proteomic-clock literature by comparing five published SomaScan clocks across mortality and 24 diseases, adding an ensemble measure and independent mortality replication. The advance consolidates and extends an established concept rather than introducing a new one.

Abstract; Results, Study population; Results, Whitehall II mortality analysis

“Replication was conducted in the Whitehall II study.”

Methodological Rigour
3.8

The case–cohort analysis uses Prentice weighting, age-scale Cox models, prespecified adjustment, FDR control, and lag and never-smoker sensitivity analyses. Single imputation, residual confounding, mortality-only replication, and unclear validation and weighting of prediction metrics limit methodological certainty.

Methods, Statistics and reproducibility; Results, Sensitivity analyses; Figure 6j

“we applied Prentice weighting to cases outside the subcohort”

Reporting
3.9

The paper follows a traceable progression from clock calculation through disease associations, replication, organ analyses, and prediction. Localized inconsistencies in the final Discussion and figure captions, plus causal-leaning geroscience and lifestyle language, reduce precision without obscuring the principal results.

Abstract; Results, organ-specific analyses; Discussion, final paragraph

“organ-specific proteomic clocks showed stronger prediction of kidney, lung and liver cancers.”

Positioning
3.8

The Discussion compares findings with SomaScan and Olink studies and identifies limitations involving baseline measurement, confounding, ethnicity, genetics, and causality. The cross-sectional lifestyle limitation is not fully carried through to the lifestyle-aging interpretation, and comparison with simpler clinical biomarkers remains limited.

Discussion, prior-study comparison and limitations paragraphs

“the risk factor analysis was cross-sectional”

Reliability

Caveats4 of 4 checks


Results checkNoted
  • Lung, kidney and stomach cancers were more strongly associated with related organ-specific age gaps: "organ-specific proteomic clocks showed stronger prediction of kidney, lung and liver cancers." (Discussion, final paragraph) vs "In some cases, organ-specific clocks showed stronger associations with diseases related to their organ such as for the kidney age gap and kidney cancer (HR 1.63, 95% CI 1.36 to 1.94; Fig. 6c), lung age gap and lung cancer (HR 1.44, 95% CI 1.30 to 1.59; Fig. 6d) and intestine age gap and stomach cancer (HR 1.40, 95% CI 1.20 to 1.64; Fig. 6e)." (Results, Associations of organ-specific proteomic age gaps with mortality and incident diseases). The final Discussion names liver cancer, whereas the reported organ-specific results identify stomach cancer alongside kidney and lung cancers. → Not supported by the paper's own data
Reporting and transparencyNoted

Figure captions mislabel the number of incident diseases, and the prediction-method description does not explicitly establish whether case–cohort weighting was used for the reported performance metrics.

Ethics approval: declared · Preregistration: not stated · Data availability: declared · Code availability: not stated

Reference IntegrityClean

45 references in manuscript 43 of 43 checkable references found in an index 2 have no canonical index record — counted, but not index-checkable 2 references confirmed by manual review

References not verified automatically are resolved manually within 24 hours.

Post-Publication RecordClean

No retraction or expression of concern found in Crossref (includes Retraction Watch).

Last checked: 17 Oct 2026

Sources: Crossref (incl. Retraction Watch) ✓

Impact Profile

Impact areaHealth · Generic health relevance
Type of advanceEmpirical
Route to useNamed
AdvanceExtends
CitationsToo early
Policy · patentNot yet traced
ReachedNot reachedNot assessable or unverified
ReadinessValidated
Foundational
Controlled
Piloted
Validated
Implementable
FoundationalImplementable

The primary associations were observed prospectively in the large EPIC cohort and the mortality findings were replicated in the independent Whitehall II cohort, but no operational use is shown.

From the paper
“randomized controlled trials in primary care are needed to determine whether integrating proteomic age into existing risk models enhances prediction, guides treatment”

The paper names primary care and clinical risk models as the setting and purpose where these findings would be applied, though their integration is still untested.

Pathway

Clinicians and trial teams in primary care would integrate proteomic age measures into risk models to stratify patients and guide preventive treatment of age-related diseases.

Barrier

Evidence is observational, and randomised trials in primary care are still needed to show that adding proteomic age to risk models improves decisions and outcomes.

Evaluated 13 Nov 2026 · GBD 2023 · glm_v1_3_3 · impact_profile_v1_3_3

Report an issue →

AI-generated, human-governed. Something look off? Contact us to request a review.

Keep reading

Related evaluations

Other papers Nabu has evaluated blind, starting with the same field.

  1. Plasma proteomic signatures of cellular aging predict human disease

    Ding, Bot, Chen, et al. · 2026 · Clinical medicine

    Primary claim

    Cellular aging signatures were associated with disease status and predicted incident disease and mortality over 15 years of follow-up.

    Tentative
    Evidence Score
    3.0±0.2
    Reliability
    Caveats
  2. Platelet-derived factors dysregulate placental sphingosine-1-phosphate receptor 2 in human trophoblasts

    Freya Lyssy, Jacqueline Guettler, Beatrice A Brugger, et al. · 2023 · Basic medicine

    Primary claim

    S1PR2 was found to be significantly down-regulated in BeWo cells when co-incubated with platelet-derived factors (P = 0.0055).

    Tentative
    Evidence Score
    3.1±0.2
    Reliability
    Caveats
  3. The endogenous exposome of the pregnant mother: Placental extracellular vesicles and their effect on the maternal system

    Nadja Kupper, Berthold Huppertz · 2021 · Basic medicine

    Primary claim

    in pregnancy pathologies such as preeclampsia, quantity and quality of the placenta-derived vesicles are altered leading to a deleterious effect on the maternal vascular system.

    Tentative
    Evidence Score
    3.2±0.1
    Reliability
    Caveats

How the rubric works →